{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:08:19Z","timestamp":1793513299487,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T00:00:00Z","timestamp":1726963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). This post hoc analysis reports the efficacy and safety of etrasimod based on baseline corticosteroid (CS) use in the ELEVATE UC clinical program.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with UC received etrasimod 2\u00a0mg or placebo for up to 52 weeks. CS use was permitted; tapering was recommended from Week 12. Efficacy was assessed at Weeks 12 and 52 in ELEVATE UC 52, and Week 12 in ELEVATE UC 12, for patients in the CS and no-CS subgroups. CS-free efficacy at Week 52 was assessed in patients with baseline CS use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In ELEVATE UC 52 and ELEVATE UC 12, 93 of 289 (32.2%) and 65 of 238 (27.3%) patients receiving etrasimod and 42 of 144 (29.2%) and 34 of 116 (29.3%) patients receiving placebo, respectively, had concomitant CS use at baseline. In the CS and no-CS subgroups, higher proportions of patients who received etrasimod vs placebo achieved clinical remission (p\u2005&amp;lt;\u20050.05) in ELEVATE UC 52 at Week 12 (CS: 32.3% vs 16.7%; no-CS: 26.0% vs 4.9%) and Week 52 (CS: 31.2% vs 9.5%; no-CS: 33.2% vs 6.9%). In the CS subgroup, significantly more patients receiving etrasimod achieved CS-free clinical remission at Week 52 (31.2% vs 7.1%) compared with those receiving placebo. No increases in infection rates were observed with baseline CS use. Safety was comparable between subgroups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Etrasimod demonstrated efficacy in inducing and maintaining remission in both subgroups. CS-free remission was achieved in the CS subgroup. Safety was consistent, with no increase in infections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trial Identifiers<\/jats:title>\n                  <jats:p>NCT03945188; NCT03996369.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjae150","type":"journal-article","created":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T05:55:58Z","timestamp":1726984558000},"source":"Crossref","is-referenced-by-count":7,"title":["Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program"],"prefix":"10.1093","volume":"19","author":[{"given":"Bruce E","family":"Sands","sequence":"first","affiliation":[{"name":"Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8699-4370","authenticated-orcid":false,"given":"Yvette","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-1723","authenticated-orcid":false,"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4830-142X","authenticated-orcid":false,"given":"Krisztina B","family":"Gecse","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center Department of Gastroenterology and Hepatology, , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-6902","authenticated-orcid":false,"given":"Julian","family":"Pan\u00e9s","sequence":"additional","affiliation":[{"name":"Formerly Department of Gastroenterology, Hospital Cl\u00ednic de Barcelona, IDIBAPS, CIBERehd , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Goetsch","sequence":"additional","affiliation":[{"name":"Pfizer AG , Z\u00fcrich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjin","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Collegeville, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Woolcott","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Collegeville, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina C","family":"Smith","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Collegeville, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Wosik","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Kirkland, QC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[{"name":"University Hospital Schleswig-Holstein, Kiel University Department of Internal Medicine, , Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,22]]},"reference":[{"key":"2025032700481021700_CIT0001","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2025032700481021700_CIT0002","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2025032700481021700_CIT0003","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2025032700481021700_CIT0004","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1053\/j.gastro.2022.06.068","article-title":"CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease","volume":"163","author":"Ma","year":"2022","journal-title":"Gastroenterology"},{"key":"2025032700481021700_CIT0005","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/apt.15497","article-title":"Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients","volume":"50","author":"Selinger","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025032700481021700_CIT0006","doi-asserted-by":"crossref","first-page":"e0212989","DOI":"10.1371\/journal.pone.0212989","article-title":"Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"14","author":"Motoya","year":"2019","journal-title":"PLoS One"},{"key":"2025032700481021700_CIT0007","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2025032700481021700_CIT0008","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ibd\/izz193","article-title":"Corticosteroid-free remission vs overall remission in clinical trials of moderate-severe ulcerative colitis and Crohn\u2019s disease","volume":"26","author":"George","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2025032700481021700_CIT0009","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"2025032700481021700_CIT0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/17474124.2019.1604219","article-title":"A current overview of corticosteroid use in active ulcerative colitis","volume":"13","author":"Salice","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2025032700481021700_CIT0011","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2010.12.028","article-title":"Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis","volume":"9","author":"Ardizzone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025032700481021700_CIT0012","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/MIB.0000000000001261","article-title":"Safety considerations with the use of corticosteroids and biologic therapies in mild-to-moderate ulcerative colitis","volume":"23","author":"Cross","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2025032700481021700_CIT0013","doi-asserted-by":"crossref","first-page":"e001220","DOI":"10.1136\/bmjdrc-2020-001220","article-title":"Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis","volume":"8","author":"Wu","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2025032700481021700_CIT0014","doi-asserted-by":"crossref","first-page":"S494","DOI":"10.14309\/00000434-201410002-01667","article-title":"Analysis of risk factors for avascular necrosis in inflammatory bowel disease [abstract 1667]","volume":"109","author":"Yadav","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2025032700481021700_CIT0015","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"2025032700481021700_CIT0016","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/j.1572-0241.2008.01836.x","article-title":"Immunosuppressant medications and mortality in inflammatory bowel disease","volume":"103","author":"Lewis","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"2025032700481021700_CIT0017","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/ecco-jcc\/jjad190","article-title":"Impact of baseline corticosteroid use on the efficacy and safety of upadacitinib in patients with ulcerative colitis: a post hoc analysis of the phase 3 clinical trial programme","volume":"18","author":"Raine","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2025032700481021700_CIT0018","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/MEG.0000000000000378","article-title":"Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn\u2019s disease: a systematic review and clinician surveys","volume":"27","author":"Gordon","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025032700481021700_CIT0019","first-page":"564","article-title":"Ulcerative colitis\u2014diagnostic and therapeutic algorithms","volume":"117","author":"Kucharzik","year":"2020","journal-title":"Dtsch Arztebl Int"},{"key":"2025032700481021700_CIT0020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000496739","article-title":"Unmet medical needs in ulcerative colitis: an expert group consensus","volume":"37","author":"Danese","year":"2019","journal-title":"Dig Dis"},{"key":"2025032700481021700_CIT0021","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"2025032700481021700_CIT0022","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"2025032700481021700_CIT0023","doi-asserted-by":"crossref","first-page":"17562848221090834","DOI":"10.1177\/17562848221090834","article-title":"Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE sustain maintenance study","volume":"15","author":"Vavricka","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"2025032700481021700_CIT0024","doi-asserted-by":"crossref","first-page":"i089","DOI":"10.1093\/ecco-jcc\/jjab232.079","article-title":"Impact of corticosteroid usage on efficacy and safety outcomes in patients receiving upadacitinib for ulcerative colitis","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2025032700481021700_CIT0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/CEG.S248597","article-title":"Sustained corticosteroid-free clinical remission during vedolizumab maintenance therapy in patients with ulcerative colitis on stable concomitant corticosteroids during induction therapy: a post hoc analysis of GEMINI 1","volume":"13","author":"Loftus","year":"2020","journal-title":"Clin Exp Gastroenterol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjae150\/59225989\/jjae150.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/3\/jjae150\/59787659\/jjae150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/3\/jjae150\/59787659\/jjae150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T22:55:46Z","timestamp":1743288946000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjae150\/7764041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,22]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae150","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,9,22]]},"article-number":"jjae150"}}